Glenview Capital Management initiated a new $96.45 million position in DigitalOcean Holdings during Q4 2025, acquiring 2,004,299 shares. The investment became the fund's 11th-largest holding at 1.96% of AUM. DigitalOcean reported strong earnings with 18% revenue growth, 123% spike in ARR from $1M+ customers, and 150% AI ARR growth, positioning itself as a platform for high-growth cloud and AI workloads.

The article recommends two healthcare stocks for February 2026: CVS Health and Vertex Pharmaceuticals. CVS Health is positioned for long-term profitable growth after a strong 2025 rebound, with plans to streamline its Medicare Advantage and Obamacare businesses. Vertex Pharmaceuticals is expected to see strong commercial progress from newer drug launches (Casgevy and Journavx) and important clinical developments in 2026, diversifying beyond its core cystic fibrosis franchise.

Salvation Army has relocated from Gordon Plaza to a new 19,000 square foot space at Woodbridge Shopping Center in Virginia, positioned at the corner of Route 1 and Occoquan Road. The move follows Gordon Plaza's closure for redevelopment and allows Salvation Army to maintain its presence in the Woodbridge corridor with improved visibility and traffic. The shopping center is co-anchored by CVS and Dixie Bones.

The global clinical analytics market is experiencing rapid expansion driven by widespread EHR adoption, AI/ML advancements, and real-world evidence acceptance. The market is projected to grow at a 19.7% CAGR from $33.09 billion in 2025 to $81.32 billion by 2030, with Asia-Pacific leading regional growth. Key drivers include digital health adoption, value-based care transition, and precision medicine demand.

Kiltearn Partners LLP fully exited its position in Sealed Air Corporation by selling 335,500 shares in Q4, according to an SEC filing. The position had represented 2.4% of the fund's assets under management. Despite Sealed Air's strong 26.3% return over the past year, the company faces headwinds with Q3 sales declining 1% and management expecting 2-3% sales decline for the full year.

Hendricks Commercial Properties successfully sold Island Plaza, a CVS-anchored retail center on Marco Island, for $26.6 million in late 2025. The property, originally acquired in 2013 for $12.5 million, delivered approximately 2.5x equity multiple with an estimated 12-year IRR of 9-13%, demonstrating strong long-term performance in the coastal Florida retail market.

CVS Health reported Q4 sales of $105.69 billion, beating consensus estimates, with adjusted EPS of $1.09 versus expected 99 cents. The company reaffirmed its 2026 adjusted earnings guidance of $7.00-$7.20 per share and projects revenue of at least $400 billion. Bank of America Securities maintains a Buy rating with a $95 price target, citing multiple growth levers including Medicare Advantage repricing, Rite Aid acquisitions, and margin improvements in health services to offset 2027 headwinds.

CVS Health reported Q4 2025 results beating revenue and earnings expectations with $105.69B in sales and $1.09 EPS versus consensus estimates. However, the company lowered its 2026 cash flow guidance to at least $9.0B from $10.0B and provided 2026 revenue guidance of at least $400B below consensus of $409.77B. CVS reaffirmed adjusted earnings guidance of $7.00-$7.20 per share for fiscal 2026.

CVS Health will report Q4 2025 earnings on Feb. 10, with potential guidance concerns due to lower-than-expected Medicare Advantage payment rate increases (0.9%). While CVS shares fell over 14% on this news, the company's diversified business model (retail pharmacy, PBM, insurance) may be less impacted than pure insurance competitors. Trading at under 11x forward earnings versus UnitedHealth's 16x, CVS could rally on 'better than feared' results despite near-term earnings volatility.

CVS Health announced it will add biosimilar medications Ospomyv and Stoboclo, along with generic teriparatide products, to its formularies starting April 1, 2026, replacing branded drugs from Amgen and Eli Lilly. The move aims to reduce prescription drug costs by more than 50% per prescription. CVS previously achieved $1.5 billion in gross savings by replacing AbbVie's Humira with biosimilars.

The FTC finalized a settlement with Cigna's Express Scripts pharmacy benefit manager to reduce anticompetitive practices and lower insulin costs by up to $7 billion over the next decade. Cigna reported strong Q4 2025 earnings, beating revenue and EPS estimates, and increased its quarterly dividend to $1.56 per share. The stock rose 3.53% following the announcement.

CVS Health faces significant headwinds as the Trump administration proposed minimal Medicare Advantage rate increases of just 0.09% for 2027, far below analyst expectations of 4-6%. With over one-third of CVS revenue from its healthcare benefits segment (Aetna), combined with rising medical costs pressuring already thin single-digit margins, the stock appears risky despite its cheap valuation and recent 77% gain in 2025.